aTyr Pharma ATYR Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$70.03M-10.4% | -$74.12M-15.8% | -$75.13M-17.7% | -$66.64M-15.1% | -$63.42M-17.6% | ||
| $659K-5.5% | $664K-6.2% | $673K-4.9% | $686K-2.8% | $697K+1.0% | ||
| $5.13M+49.6% | $5M+67.2% | $4.56M+58.4% | $4.01M+43.5% | $3.43M+25.9% | ||
| $822K— | -$33K— | —— | —— | —— | ||
| -$5.98M— | -$8.05M— | —— | —— | —— | ||
| $905K— | $889K— | —— | —— | —— | ||
| -$740K— | -$711K— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$59.08M+4.9% | -$61.99M+10.3% | -$62.92M+6.2% | -$55.6M+12.4% | -$62.16M-13.0% | ||
| $215K+348% | $77K+18.5% | $71K+24.6% | $49K-91.8% | $48K-98.4% | ||
| $76.21M+7.5% | $93.45M+35.2% | $106.67M+102% | $70.24M-10.4% | $70.87M-13.7% | ||
| $87.27M+2.6% | $88.46M+2.4% | $79.15M-15.7% | $81.02M-24.0% | $85.08M-16.4% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | $19K— | $2K— | ||
| $550K+8.5% | $539K+8.5% | $528K+9.1% | $517K+10.7% | $507K+12.9% | ||
| $47.37M-6.9% | $66.14M+65.5% | $84.98M+213% | $55.36M+85.5% | $50.87M+108% | ||
| —— | —— | -$5.52M— | —— | —— | ||
| $83K-34.6% | $94K-31.4% | $105K-28.1% | $116K-23.7% | $127K-22.6% | ||
| $1.59M-34.4% | $1.85M-31.5% | $2.04M-33.0% | $2.14M-37.4% | $2.42M-32.2% | ||
| $5.13M+49.6% | $5M+67.2% | $4.56M+58.4% | $4.01M+43.5% | $3.43M+25.9% | ||
| -$740K— | -$711K— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$5.98M— | -$8.05M— | —— | —— | —— | ||
| $905K— | $889K— | —— | —— | —— | ||
| $87.27M+2.6% | $88.46M+2.4% | $79.15M-15.7% | $81.02M-24.0% | $85.08M-16.4% | ||
| $550K+8.5% | $539K+8.5% | $528K+9.1% | $517K+10.7% | $507K+12.9% | ||
| $47.69M-6.8% | $66.44M+65.0% | $85.35M+211% | $55.62M+84.0% | $51.17M— | ||
| —— | —— | —— | $19K— | $2K— | ||
| -$740K— | -$711K— | —— | —— | —— | ||
| —— | $0— | $0— | $0-100% | $0-100% | ||
| —— | —— | —— | —— | —— | ||
| -$59.3M+4.7% | -$62.06M+10.3% | -$62.99M+6.1% | -$55.65M+13.1% | -$62.21M-7.3% | ||
| -$59.3M+4.7% | -$62.06M+10.3% | -$62.99M+6.1% | -$55.65M+13.1% | -$62.21M-7.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does aTyr Pharma generate?
- aTyr Pharma (ATYR) generated -$59.1M in operating cash flow over the trailing twelve months.
- What is aTyr Pharma's free cash flow?
- After $215.0K of capital expenditures, aTyr Pharma's free cash flow was -$59.3M over the trailing twelve months, up 4.7% year over year.
- Where does aTyr Pharma's cash flow data come from?
- Every line is extracted from aTyr Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
